BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

14-Feb-2024 - BioNTech SE and Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory ...

BioNTech and Medigene announce global collaboration to advance T cell receptor immunotherapies against cancer

Medigene will receive EUR 26 million upfront from BioNTech

23-Feb-2022 - BioNTech SE and Medigene AG announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years. Medigene will contribute its proprietary TCR discovery platform for the ...

BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

20-Jul-2021 - BioNTech SE andKite, a Gilead Company announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will ...